# OnCo record amivantamab-plus-lazertinib (pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pairings/amivantamab-plus-lazertinib/>
  a schema:MedicalTherapy ;
  onco:kind "pairing" ;
  schema:identifier "amivantamab-plus-lazertinib" ;
  schema:name "Amivantamab + lazertinib (first-line EGFR NSCLC)"@en ;
  schema:description "Blocking EGFR from inside (a pill) and outside (an antibody that also blocks MET) beat osimertinib and added more than a year of survival."@en ;
  schema:url <https://onco.cc/pairings/amivantamab-plus-lazertinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04487080> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:terms <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/c797s/> ;
  onco:trials <https://onco.cc/trials/mariposa/> ;
  onco:pairs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/> .